The Implications of New Research Findings for the Management of Endometrial Cancer
Oncology Today with Dr Neil Love
00:00
The Progression Free Survival of Pembrolizumab
018 is a similar trial, but this statistical design is different. It's carbon plant and pectylotaxle plus minus pembrolizumab. The study did have a good racial admirct of non-Hispanic Black patients. And then just shown in tabular form I really think clinically meaning PFS benefits, an OS trend that looks to be maintaining significance and acceptable safety profile.
Transcript
Play full episode
